Protein expression pattern in experimental pneumococcal meningitis.
In this study, we investigated cytokine expression during experimental pneumococcal meningitis. Mice were intracisternally infected with Streptococcus pneumoniae and treated with ceftriaxone starting at 24 h after infection. At different time points before and after antibiotic therapy, the cytokine expression pattern was determined in mouse brains using protein arrays. Underlining the power of this method, the meningitis-relevant cytokines interleukin-1beta (IL-1beta), IL-6, KC, macrophage inflammatory protein-2 (MIP-2), and monocyte chemoattractant protein-1 (MCP-1/CCL2) were markedly elevated in infected animals. Newly identified proteins during the acute stage of the disease (until 30 h after infection) included lymphotactin (XCL-1), MIP-1gamma (CCL9) and MCP-5 (CCL12), cytokine responsive gene- 2 (CRG-2/CXCL10) and CXCL16, and insulin-like growth factor binding protein 3 (IGFBP3). During later stages, an induction of T-cell activation-3 (TCA-3/CCL1), platelet factor-4 (PF-4/CXCL4) and stromal derived factor-1alpha (SDF-1alpha/CXCL13), and IL-4 was observed. The validity of this method was supported by an additional ELISA analysis of the expression profile of CXCL16 and IGFBP3, which was identical to that observed by protein array. In conclusion, the use of protein array technology led to an extension of the current picture of protein expression in pneumococcal meningitis. Most important, new factors that might play a role in pneumococcal meningitis were identified.
Klein
Matthias
M
Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilian University, Marchioninistrasse 15, 81377 Munich, Germany.
Paul
Robert
R
Angele
Barbara
B
Popp
Bernadette
B
Pfister
Hans-Walter
HW
Koedel
Uwe
U
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001921:Brain / Q000276:immunology / Q000378:metabolism*; D002443:Ceftriaxone / Q000627:therapeutic use; D054357:Chemokine CXCL10; D054382:Chemokine CXCL13; D019744:Chemokines, C / Q000096:biosynthesis*; D019742:Chemokines, CC; D019743:Chemokines, CXC / Q000096:biosynthesis; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D015847:Interleukin-4 / Q000096:biosynthesis; D019402:Macrophage Inflammatory Proteins / Q000096:biosynthesis*; D008586:Meningitis, Pneumococcal / Q000188:drug therapy / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018945:Monocyte Chemoattractant Proteins / Q000096:biosynthesis*; D015846:Monokines / Q000096:biosynthesis*; D010978:Platelet Factor 4 / Q000096:biosynthesis*; D040081:Protein Array Analysis; D013296:Streptococcus pneumoniae; D013997:Time Factors
D000900:Anti-Bacterial Agents; C491224:Ccl12 protein, mouse; C095218:Ccl9 protein, mouse; D054357:Chemokine CXCL10; D054382:Chemokine CXCL13; D019744:Chemokines, C; D019742:Chemokines, CC; D019743:Chemokines, CXC; C485433:Cxcl10 protein, mouse; C486386:Cxcl13 protein, mouse; D016207:Cytokines; D019402:Macrophage Inflammatory Proteins; D018945:Monocyte Chemoattractant Proteins; D015846:Monokines; C486249:Xcl1 protein, mouse; D015847:Interleukin-4; D010978:Platelet Factor 4; D002443:Ceftriaxone